Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Earnings for Evoke Pharma, Inc. (EVOK)
Earnings in 2023 (TTM): $-7,792,295
According to Evoke Pharma, Inc.'s latest financial reports the company's current earnings (TTM) are $-7,792,295. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Evoke Pharma, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-7,792,295 | $-7,792,295 |
| 2022 | $-8,224,130 | $-8,162,123 |
| 2021 | $-8,537,952 | $-9,029,387 |
| 2020 | $-13,154,671 | $-13,261,993 |
| 2019 | $-7,125,655 | $-7,096,857 |
| 2018 | $-7,566,080 | $-7,566,080 |
| 2017 | $-12,229,512 | $-12,229,512 |
| 2016 | $-10,748,531 | $-10,748,531 |
| 2015 | $-12,121,463 | $-12,121,463 |
| 2014 | $-13,247,681 | $-13,247,681 |
| 2013 | $-2,836,465 | $-2,836,465 |
| 2012 | $-2,017,528 | $-2,017,528 |
| 2011 | $-2,401,244 | $-2,401,244 |